Litigation Details for SALIX PHARMACEUTICALS, INC. v. ZYDUS PHARMACEUTICALS (USA), INC. (D.N.J. 2022)

SALIX PHARMACEUTICALS, INC. v. ZYDUS PHARMACEUTICALS (USA), INC. (D.N.J. 2022)

Docket		Date Filed	2022-09-16
Court	District Court, D. New Jersey	Date Terminated	2023-03-06
Cause	35:271 Patent Infringement	Assigned To	Julien Xavier Neals
Jury Demand	None	Referred To	Jose R. Almonte
Patents	7,452,872; 7,625,884; 8,497,256
Link to Docket	External link to docket

Details for SALIX PHARMACEUTICALS, INC. v. ZYDUS PHARMACEUTICALS (USA), INC. (D.N.J. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-09-16				External link to document

Litigation summary and analysis for: SALIX PHARMACEUTICALS, INC. v. ZYDUS PHARMACEUTICALS (USA), INC. (D.N.J. 2022)

Last updated: July 18, 2026

SALIX PHARMACEUTICALS, INC. v. ZYDUS PHARMACEUTICALS (USA), INC. (2:22-cv-05589): Litigation Summary, Claims at Issue, and Patent/Entitlement Exposure

Salix Pharmaceuticals, Inc. v. Zydus Pharmaceuticals (USA), Inc., docketed as 2:22-cv-05589, is a US Hatch-Waxman patent litigation matter initiated by Salix in 2022 against Zydus. The case record is required to identify the asserted patents, ANDA number, drug product, filing posture (Paragraph IV vs other), claim-by-claim allegations, district court holdings, and any settlement or dismissal. Without those case-specific documents and filings, a complete litigation summary and patent strength analysis cannot be produced.

What patent estate is at issue in SALIX vs ZYDUS 2:22-cv-05589?

A litigation summary for this docket must start with the asserted Orange Book patents and the specific patents Salix alleges are infringed. The following items are necessary to produce a factual, actionable analysis:

• ANDA number tied to Zydus’s filing
• Brand/generic drug product identity
• Patent list from the complaint (numbers, expiration dates, and assignees)
• Salix’s infringement theories (product claim, formulation, method of use, dosage form, manufacturing method)

Result: Case-specific patent identifiers and infringement theories are not available from the docket number alone, and therefore the patent estate cannot be mapped for this case.

How many patents does Salix typically assert in Hatch-Waxman filings like this?

Patent counts vary by product and Orange Book inventory. A proper count requires the complaint and any amended pleadings.

Result: Not determinable without the complaint and patent schedule.

What is the Paragraph IV and FDA exclusivity posture for 2:22-cv-05589?

A correct exclusivity and FDA posture analysis requires:

• the ANDA paragraph certification(s) tied to the Orange Book patents
• whether certifications were Paragraph IV (frequently tied to “due to expire” or “invalid/unenforceable” arguments)
• whether additional forfeiture issues were alleged
• the FDA approval status and any 505(j) timing

Result: The certification type and FDA status cannot be determined without the ANDA certification record or complaint.

When does exclusivity end and when can Zydus enter?

Entry timing depends on:

• patent expiration dates and any statutory extensions (including pediatric exclusivity where applicable)
• marketing exclusivity (if relevant to the listed patents)
• 180-day exclusivity triggers (first-filer status, etc.)

Result: No expiration/exclusivity schedule can be built for this docket without the asserted patent list and drug.

Which court decisions and claim constructions affect the SALIX vs ZYDUS case?

Litigation analysis hinges on the district court’s rulings on:

• claim construction (Markman) and how that constrains infringement/invalidity
• motions to dismiss (indefiniteness, failure to state a claim, improper pleading, standing)
• summary judgment on infringement or invalidity
• evidentiary rulings affecting trial readiness

Result: Decision dates, holdings, and constructed claims cannot be summarized without accessing the court orders and docket events for 2:22-cv-05589.

Did the court grant or deny preliminary injunctions?

In Hatch-Waxman, preliminary injunctions turn on likelihood of success on infringement and irreparable harm.

Result: Not determinable without the docket entry history for this case.

What settlement terms exist in 2:22-cv-05589 and how do they affect generic launch risk?

A settlement analysis requires:

• whether there was an agreement resolving the action
• whether the parties agreed to a “carve-out” entry date or licensed product changes
• payment or non-monetary consideration terms
• dismissal with prejudice, stipulated injunction terms, or covenant-not-to-sue scope

Result: No settlement or dismissal terms can be stated without the settlement document or final docket disposition.

What generic entry risks exist for Zydus if patents are invalidated or design-arounds are allowed?

Risk depends on:

• which asserted claims survive post-MJ or trial
• whether Zydus’s product design circumvents claim elements
• whether manufacturing method patents are in scope (harder to design around)
• whether there are noninfringement rulings tied to specific ranges, compositions, or process steps

Result: Cannot be analyzed without knowing the claim scope and Zydus’s ANDA-described formulation and manufacturing controls.

How strong is the patent estate for SALIX products in this dispute?

A patent strength assessment must include:

• patent family overview and prosecution history indicators
• claim breadth and construction outcomes
• prior art landscape and obviousness/anticipation posture
• enforceability issues (written description, enablement, inequitable conduct allegations)

Result: Not possible without the asserted patent set and litigation filings.

What is the Orange Book status of the patents asserted in SALIX vs ZYDUS 2:22-cv-05589?

Orange Book status analysis requires:

• listing entries for the brand product tied to the specific patents in suit
• expiration dates, pediatric exclusivity status, and any listed delist events
• current Orange Book “listed” vs “withdrawn” statuses

Result: Not possible without the drug and patent list.

How does this case compare with other Salix vs generic challenges?

A comparative analysis needs:

• the specific brand product category (GI, constipation, ulcerative colitis, hepatic encephalopathy, etc.)
• recurring Salix patent themes (formulation, pH release, dosing regimen, polymorphs, manufacturing)
• how courts have treated similar claim constructions in other cases

Result: Cannot be performed for this docket without identifying the product and asserted patents.

Timeline: What happened in SALIX PHARMACEUTICALS v. ZYDUS PHARMACEUTICALS (USA), 2:22-cv-05589?

A litigation timeline requires docket events such as:

• complaint filing date
• answer deadlines and responsive pleadings
• amended complaints
• Markman schedule and claim construction order
• summary judgment motion dates
• trial dates (if any)
• final disposition date

Result: No timeline can be provided from the docket number alone.

Tabular docket timeline (required fields)

Date	Docket event	Party	Legal significance
(Not provided)	Complaint filed	Salix	Start of Hatch-Waxman litigation; identifies asserted patents
(Not provided)	Answer/response	Zydus	Frames infringement and invalidity defenses
(Not provided)	Claim construction (order)	Court	Determines claim scope for infringement and invalidity
(Not provided)	Dispositive motions (MSJ/Daubert)	Parties	Narrows issues; can drive settlement or judgment
(Not provided)	Final judgment/settlement dismissal	Parties/Court	Determines generic entry and ongoing covenants

Key Takeaways

No complete litigation summary, patent estate mapping, exclusivity timeline, or entry-risk analysis can be produced for SALIX PHARMACEUTICALS, INC. v. ZYDUS PHARMACEUTICALS (USA), INC. (2:22-cv-05589) from the docket number alone. A factual write-up must tie the case to the specific drug, ANDA, asserted Orange Book patents, and the court’s case dispositive rulings or settlement/dismissal terms.

FAQs

1. What Orange Book patents does Salix list for its product in the Zydus case 2:22-cv-05589?
2. Was Zydus’s ANDA certification in 2:22-cv-05589 a Paragraph IV, and what did Salix allege?
3. What claim constructions did the court adopt in 2:22-cv-05589 that affect infringement analysis?
4. Did 2:22-cv-05589 end in summary judgment, trial judgment, or settlement dismissal?
5. What is the earliest likely generic entry date under the resolution of 2:22-cv-05589?

References

1. US District Court docket for SALIX PHARMACEUTICALS, INC. v. ZYDUS PHARMACEUTICALS (USA), INC., No. 2:22-cv-05589. (Court record not provided in the prompt.)